Literature DB >> 35134322

Helicobacter pylori-induced RASAL2 Through Activation of Nuclear Factor-κB Promotes Gastric Tumorigenesis via β-catenin Signaling Axis.

Longlong Cao1, Shoumin Zhu2, Heng Lu2, Mohammed Soutto2, Nadeem Bhat2, Zheng Chen2, Dunfa Peng2, Jianxian Lin3, Jun Lu3, Ping Li3, Chaohui Zheng3, Changming Huang4, Wael El-Rifai5.   

Abstract

BACKGROUND & AIMS: Helicobacter pylori infection is the predominant risk factor for gastric cancer. RAS protein activator like 2 (RASAL2) is considered a double-edged sword in carcinogenesis. Herein, we investigated the role of RASAL2 in response to H pylori infection and gastric tumorigenesis.
METHODS: Bioinformatics analyses of local and public databases were applied to analyze RASAL2 expression, signaling pathways, and clinical significance. In vitro cell culture, spheroids, patient-derived organoids, and in vivo mouse models were used. Molecular assays included chromatin immunoprecipitation, co-immunoprecipitation, Western blotting, quantitative polymerase chain reaction, and immunocyto/histochemistry.
RESULTS: H pylori infection induced RASAL2 expression via a nuclear factor-κB (NF-κB)-dependent mechanism whereby NF-κB was directly bound to the RASAL2 promoter activating its transcription. By gene silencing and ectopic overexpression, we found that RASAL2 upregulated β-catenin transcriptional activity. RASAL2 inhibited protein phosphatase 2A activity through direct binding with subsequent activation of the AKT/β-catenin signaling axis. Functionally, RASAL2 silencing decreased nuclear β-catenin levels and impaired tumor spheroids and organoids formation. Furthermore, the depletion of RASAL2 impaired tumor growth in gastric tumor xenograft mouse models. Clinicopathological analysis indicated that abnormal overexpression of RASAL2 correlated with poor prognosis and chemoresistance in human gastric tumors.
CONCLUSIONS: These studies uncovered a novel signaling axis of NF-κB/RASAL2/β-catenin, providing a novel link between infection, inflammation and gastric tumorigenesis.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastric Cancer; Helicobacter pylori; RASAL2; Tumorigenesis; β-catenin

Mesh:

Substances:

Year:  2022        PMID: 35134322      PMCID: PMC9038683          DOI: 10.1053/j.gastro.2022.01.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  57 in total

1.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

2.  Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.

Authors:  Sarah Naomi Olsen; Ania Wronski; Zafira Castaño; Benjamin Dake; Clare Malone; Thomas De Raedt; Miriam Enos; Yoko S DeRose; Wenhui Zhou; Stephanie Guerra; Massimo Loda; Alana Welm; Ann H Partridge; Sandra S McAllister; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Discov       Date:  2016-12-14       Impact factor: 39.397

Review 3.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

4.  TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.

Authors:  Fang Hua; Shuang Shang; Yu-Wei Yang; Hai-Zeng Zhang; Tian-Lei Xu; Jiao-Jiao Yu; Dan-Dan Zhou; Bing Cui; Ke Li; Xiao-Xi Lv; Xiao-Wei Zhang; Shan-Shan Liu; Jin-Mei Yu; Feng Wang; Cheng Zhang; Bo Huang; Zhuo-Wei Hu
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

Review 5.  A view on drug resistance in cancer.

Authors:  José Baselga; David M Hyman; Neil Vasan
Journal:  Nature       Date:  2019-11-13       Impact factor: 49.962

Review 6.  Targeting Cancer Stem Cells to Overcome Chemoresistance.

Authors:  Toni Nunes; Diaddin Hamdan; Christophe Leboeuf; Morad El Bouchtaoui; Guillaume Gapihan; Thi Thuy Nguyen; Solveig Meles; Eurydice Angeli; Philippe Ratajczak; He Lu; Mélanie Di Benedetto; Guilhem Bousquet; Anne Janin
Journal:  Int J Mol Sci       Date:  2018-12-13       Impact factor: 5.923

7.  DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/β-catenin signaling and cancer stem cell traits.

Authors:  Hsiang-Cheng Chi; Chung-Ying Tsai; Chia-Siu Wang; Huang-Yu Yang; Lu-Hai Wang; Wei-Jan Chen; Kwang-Huei Lin; Chien-Hui Lo; Won-Jing Wang; Kam-Fai Lee; Li-Yin Lai; Ji-Hong Hong; Yen-Fang Chang; Ming-Ming Tsai; Chau-Ting Yeh; Cheng Heng Wu; Ching-Chuan Hsieh
Journal:  Oncogene       Date:  2020-08-04       Impact factor: 9.867

Review 8.  The Wnt Signalling Pathway: A Tailored Target in Cancer.

Authors:  Malvina Koni; Veronica Pinnarò; Maria Felice Brizzi
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

View more
  4 in total

Review 1.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 2.  Current Status and Future Directions of Bacteria-Based Immunotherapy.

Authors:  Quan Tang; Xian Peng; Bo Xu; Xuedong Zhou; Jing Chen; Lei Cheng
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 3.  Applications of human organoids in the personalized treatment for digestive diseases.

Authors:  Qinying Wang; Fanying Guo; Yutao Jin; Yanlei Ma
Journal:  Signal Transduct Target Ther       Date:  2022-09-27

4.  Activation of the β‑TrCP/IκBα/inflammation axis limits the sensitivity of liver cancer cells to neddylation inhibition.

Authors:  Haojun Xiong; Dandan Zheng; Ying Liu; Lihai Ma; Lingzhan Meng; Zhenzhou Yang; Zhixiang Yang
Journal:  Oncol Rep       Date:  2022-09-28       Impact factor: 4.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.